BMS-470539

1. BMS-470539 decreases skin thickness in mice.

   “In vivo, the compound reduced skin thickness on the bleomycin-induced skin fibrosis murine model when administered intraperitoneally”

   Animalsbleomycin-induced skin fibrosis

   The senescence-like activity of BMS-470539 is associated with anti-fibrotic actions in models of dermal fibrosis

   Arthritis research & therapy·30 Sep 2025

More on Skin thickness

1. BMS-470539 decreases ACTA2 in human cells.

   “resulted in the downregulation of fibrosis markers including ⍺-smooth muscle actin, migration, CCL2 and genes related to TGFβ and fibroblast activation.”

   Cellsin systemic sclerosis fibroblasts

   The senescence-like activity of BMS-470539 is associated with anti-fibrotic actions in models of dermal fibrosis

   Arthritis research & therapy·30 Sep 2025

More on ACTA2

1. BMS-470539 induces cellular senescence in human cells.

   “BMS-470539 induced a 'senescence-like' state in human dermal fibroblasts from systemic sclerosis patients”

   Cellsin systemic sclerosis fibroblasts

   The senescence-like activity of BMS-470539 is associated with anti-fibrotic actions in models of dermal fibrosis

   Arthritis research & therapy·30 Sep 2025

More on Cellular senescence